Cargando…

Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study

BACKGROUND AND OBJECTIVES: Candida albicans is a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML). Prolonged use of fluconazole as empirical antifungal prophylaxis in AML patients leads to overexpression of efflux pump genes that resulted in the emergence...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayed, Shereen A, Hassan, Ehsan A B, Abdel Hameed, Muhamad R, Agban, Michael N, Mohammed Saleh, Mostafa F, Mohammed, Hayam H, Abdel-Aal, Abu-Baker M, Elgendy, Sherein G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214543/
https://www.ncbi.nlm.nih.gov/pubmed/34163275
http://dx.doi.org/10.2147/JBM.S302158
_version_ 1783710085937102848
author Sayed, Shereen A
Hassan, Ehsan A B
Abdel Hameed, Muhamad R
Agban, Michael N
Mohammed Saleh, Mostafa F
Mohammed, Hayam H
Abdel-Aal, Abu-Baker M
Elgendy, Sherein G
author_facet Sayed, Shereen A
Hassan, Ehsan A B
Abdel Hameed, Muhamad R
Agban, Michael N
Mohammed Saleh, Mostafa F
Mohammed, Hayam H
Abdel-Aal, Abu-Baker M
Elgendy, Sherein G
author_sort Sayed, Shereen A
collection PubMed
description BACKGROUND AND OBJECTIVES: Candida albicans is a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML). Prolonged use of fluconazole as empirical antifungal prophylaxis in AML patients leads to overexpression of efflux pump genes that resulted in the emergence of azole-resistant species. Consequently, the introduction of a new strategy to improve the management of C. albicans infections is an urgent need. Nonsteroidal anti-inflammatory drug (NSAID) ketorolac is associated with a reduction in cancer relapses. The present study was performed to investigate the use of ketorolac-fluconazole combination to reverse fluconazole resistance in C. albicans isolated from AML patients on induction chemotherapy. PATIENTS AND METHODS: One hundred and seventy AML patients were evaluated. Fifty C. albicans were isolated and subjected to disc diffusion assay and broth microdilution for fluconazole alone and combined with different concentrations of ketorolac. Efflux pump gene (CDR1, CDR2, and MDR1) expressions were quantified by real-time PCR. RESULTS: The tested ketorolac acted synergistically with fluconazole against resistant C. albicans with the minimum inhibitory concentration (MIC) of fluconazole decreased from >160 μg/mL to 0.3–1.25 μg/mL in (93.8%) of resistant isolates with fractional inhibitory concentration index (FICI) value of 0.25. The majority of the resistant isolates overexpressed CDR1 (71.1%) and MDR1 (60%). CONCLUSION: Ketorolac-fluconazole in vitro combination would be a promising strategy for further clinical in vivo trials to overcome fluconazole resistance in AML patients on induction chemotherapy.
format Online
Article
Text
id pubmed-8214543
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82145432021-06-22 Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study Sayed, Shereen A Hassan, Ehsan A B Abdel Hameed, Muhamad R Agban, Michael N Mohammed Saleh, Mostafa F Mohammed, Hayam H Abdel-Aal, Abu-Baker M Elgendy, Sherein G J Blood Med Original Research BACKGROUND AND OBJECTIVES: Candida albicans is a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML). Prolonged use of fluconazole as empirical antifungal prophylaxis in AML patients leads to overexpression of efflux pump genes that resulted in the emergence of azole-resistant species. Consequently, the introduction of a new strategy to improve the management of C. albicans infections is an urgent need. Nonsteroidal anti-inflammatory drug (NSAID) ketorolac is associated with a reduction in cancer relapses. The present study was performed to investigate the use of ketorolac-fluconazole combination to reverse fluconazole resistance in C. albicans isolated from AML patients on induction chemotherapy. PATIENTS AND METHODS: One hundred and seventy AML patients were evaluated. Fifty C. albicans were isolated and subjected to disc diffusion assay and broth microdilution for fluconazole alone and combined with different concentrations of ketorolac. Efflux pump gene (CDR1, CDR2, and MDR1) expressions were quantified by real-time PCR. RESULTS: The tested ketorolac acted synergistically with fluconazole against resistant C. albicans with the minimum inhibitory concentration (MIC) of fluconazole decreased from >160 μg/mL to 0.3–1.25 μg/mL in (93.8%) of resistant isolates with fractional inhibitory concentration index (FICI) value of 0.25. The majority of the resistant isolates overexpressed CDR1 (71.1%) and MDR1 (60%). CONCLUSION: Ketorolac-fluconazole in vitro combination would be a promising strategy for further clinical in vivo trials to overcome fluconazole resistance in AML patients on induction chemotherapy. Dove 2021-06-15 /pmc/articles/PMC8214543/ /pubmed/34163275 http://dx.doi.org/10.2147/JBM.S302158 Text en © 2021 Sayed et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sayed, Shereen A
Hassan, Ehsan A B
Abdel Hameed, Muhamad R
Agban, Michael N
Mohammed Saleh, Mostafa F
Mohammed, Hayam H
Abdel-Aal, Abu-Baker M
Elgendy, Sherein G
Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title_full Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title_fullStr Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title_full_unstemmed Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title_short Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study
title_sort ketorolac-fluconazole: a new combination reverting resistance in candida albicans from acute myeloid leukemia patients on induction chemotherapy: in vitro study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214543/
https://www.ncbi.nlm.nih.gov/pubmed/34163275
http://dx.doi.org/10.2147/JBM.S302158
work_keys_str_mv AT sayedshereena ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT hassanehsanab ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT abdelhameedmuhamadr ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT agbanmichaeln ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT mohammedsalehmostafaf ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT mohammedhayamh ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT abdelaalabubakerm ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy
AT elgendyshereing ketorolacfluconazoleanewcombinationrevertingresistanceincandidaalbicansfromacutemyeloidleukemiapatientsoninductionchemotherapyinvitrostudy